目次

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations

3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation

4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities

5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis

6. GLOBAL NEURODEGENERATIVE DISEASE MARKET, BY TYPE
6.1. Overview
6.2. NMDA
6.3. SSRIs
6.4. Dopamine Inhibitors

7. GLOBAL NEURODEGENERATIVE DISEASE MARKET, BY DISEASE INDICATION
7.1. Overview
7.2. Parkinson’s disease
7.3. Alzheimer's disease
7.4. Amyotrophic Lateral Sclerosis
7.5. Huntington disease

8. GLOBAL NEURODEGENERATIVE DISEASE MARKET, BY REGION
8.1. Overview
8.1. North America
8.1.1. US
8.1.2. Canada
8.2. Europe
8.2.1. Germany
8.2.2. France
8.2.3. UK
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Europe
8.3. Asia-Pacific
8.3.1. China
8.3.2. India
8.3.3. Japan
8.3.4. South Korea
8.3.5. Australia
8.3.6. Rest of Asia-Pacific
8.4. Rest of the World
8.4.1. Middle East
8.4.2. Africa
8.4.3. Latin America

9. COMPETITIVE LANDSCAPE
9.1. Overview
9.2. Competitive Analysis
9.3. Market Share Analysis
9.4. Major Growth Strategy in the Global Neurodegenerative disease Market,
9.5. Competitive Benchmarking
9.6. Leading Players in Terms of Number of Developments in the Global Neurodegenerative disease Market,
9.7. Key developments and Growth Strategies
9.7.1. New Disease Indication Launch/Service Deployment
9.7.2. Merger & Acquisitions
9.7.3. Joint Ventures
9.8. Major Players Financial Matrix
9.8.1. Sales & Operating Income, 2022
9.8.2. Major Players R&D Expenditure. 2022

10. COMPANY PROFILES
10.1. NOVARTIS
10.1.1. Company Overview
10.1.2. Financial Overview
10.1.3. Disease Indications Offered
10.1.4. Key Developments
10.1.5. SWOT Analysis
10.1.6. Key Strategies
10.2. PFIZER
10.2.1. Company Overview
10.2.2. Financial Overview
10.2.3. Disease Indications Offered
10.2.4. Key Developments
10.2.5. SWOT Analysis
10.2.6. Key Strategies
10.3. MERCK SERONO
10.3.1. Company Overview
10.3.2. Financial Overview
10.3.3. Disease Indications Offered
10.3.4. Key Developments
10.3.5. SWOT Analysis
10.3.6. Key Strategies
10.4. BIOGEN IDEC
10.4.1. Company Overview
10.4.2. Financial Overview
10.4.3. Disease Indications Offered
10.4.4. Key Developments
10.4.5. SWOT Analysis
10.4.6. Key Strategies
10.5. TEVA PHARMACEUTICALS INDUSTRIES
10.5.1. Company Overview
10.5.2. Financial Overview
10.5.3. Disease Indications Offered
10.5.4. Key Developments
10.5.5. SWOT Analysis
10.5.6. Key Strategies
10.6. UCB
10.6.1. Company Overview
10.6.2. Financial Overview
10.6.3. Disease Indications Offered
10.6.4. Key Developments
10.6.5. SWOT Analysis
10.6.6. Key Strategies
10.7. BOEHRINGER INGELHEIM
10.7.1. Company Overview
10.7.2. Financial Overview
10.7.3. Disease Indications Offered
10.7.4. Key Developments
10.7.5. SWOT Analysis
10.7.6. Key Strategies
10.8. Sanofi S.A.
10.8.1. Company Overview
10.8.2. Financial Overview
10.8.3. Disease Indications Offered
10.8.4. Key Developments
10.8.5. SWOT Analysis
10.8.6. Key Strategies
10.9. GlaxoSmithKline
10.9.1. Company Overview
10.9.2. Financial Overview
10.9.3. Disease Indications Offered
10.9.4. Key Developments
10.9.5. SWOT Analysis
10.9.6. Key Strategies

11. APPENDIX
11.1. References
11.2. Related Reports

LIST OF TABLES
TABLE 1 GLOBAL NEURODEGENERATIVE DISEASE MARKET, SYNOPSIS, 2018-2032
TABLE 2 GLOBAL NEURODEGENERATIVE DISEASE MARKET, ESTIMATES & FORECAST, 2018-2032 (USD BILLION)
TABLE 3 GLOBAL NEURODEGENERATIVE DISEASE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 4 GLOBAL NEURODEGENERATIVE DISEASE MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 5 NORTH AMERICA: NEURODEGENERATIVE DISEASE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 6 NORTH AMERICA: NEURODEGENERATIVE DISEASE MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 7 US: NEURODEGENERATIVE DISEASE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 8 US: NEURODEGENERATIVE DISEASE MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 9 CANADA: NEURODEGENERATIVE DISEASE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 10 CANADA: NEURODEGENERATIVE DISEASE MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 1 EUROPE: NEURODEGENERATIVE DISEASE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 2 EUROPE: NEURODEGENERATIVE DISEASE MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 3 GERMANY: NEURODEGENERATIVE DISEASE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 4 GERMANY: NEURODEGENERATIVE DISEASE MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 5 FRANCE: NEURODEGENERATIVE DISEASE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 6 FRANCE: NEURODEGENERATIVE DISEASE MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 7 ITALY: NEURODEGENERATIVE DISEASE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 8 ITALY: NEURODEGENERATIVE DISEASE MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 9 SPAIN: NEURODEGENERATIVE DISEASE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 10 SPAIN: NEURODEGENERATIVE DISEASE MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 11 UK: NEURODEGENERATIVE DISEASE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 12 UK: NEURODEGENERATIVE DISEASE MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 13 REST OF EUROPE: NEURODEGENERATIVE DISEASE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 14 REST OF EUROPE: NEURODEGENERATIVE DISEASE MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 15 ASIA-PACIFIC: NEURODEGENERATIVE DISEASE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 16 ASIA-PACIFIC: NEURODEGENERATIVE DISEASE MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 17 JAPAN: NEURODEGENERATIVE DISEASE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 18 JAPAN: NEURODEGENERATIVE DISEASE MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 19 CHINA: NEURODEGENERATIVE DISEASE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 20 CHINA: NEURODEGENERATIVE DISEASE MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 21 INDIA: NEURODEGENERATIVE DISEASE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 22 INDIA: NEURODEGENERATIVE DISEASE MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 23 AUSTRALIA: NEURODEGENERATIVE DISEASE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 24 AUSTRALIA: NEURODEGENERATIVE DISEASE MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 25 SOUTH KOREA: NEURODEGENERATIVE DISEASE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 26 SOUTH KOREA: NEURODEGENERATIVE DISEASE MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 27 REST OF ASIA-PACIFIC: NEURODEGENERATIVE DISEASE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 28 REST OF ASIA-PACIFIC: NEURODEGENERATIVE DISEASE MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 29 REST OF THE WORLD: NEURODEGENERATIVE DISEASE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 30 REST OF THE WORLD: NEURODEGENERATIVE DISEASE MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 31 MIDDLE EAST: NEURODEGENERATIVE DISEASE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 32 MIDDLE EAST: NEURODEGENERATIVE DISEASE MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 33 AFRICA: NEURODEGENERATIVE DISEASE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 34 AFRICA: NEURODEGENERATIVE DISEASE MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 35 LATIN AMERICA: NEURODEGENERATIVE DISEASE MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 36 LATIN AMERICA: NEURODEGENERATIVE DISEASE MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)

LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL NEURODEGENERATIVE DISEASE MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL NEURODEGENERATIVE DISEASE MARKET
FIGURE 4 GLOBAL NEURODEGENERATIVE DISEASE MARKET, SHARE (%), BY TYPE, 2022
FIGURE 5 GLOBAL NEURODEGENERATIVE DISEASE MARKET, SHARE (%), BY DISEASE INDICATION, 2022
FIGURE 6 GLOBAL NEURODEGENERATIVE DISEASE MARKET, SHARE (%), BY REGION, 2022
FIGURE 7 NORTH AMERICA: NEURODEGENERATIVE DISEASE MARKET, SHARE (%), BY REGION, 2022
FIGURE 8 EUROPE: NEURODEGENERATIVE DISEASE MARKET, SHARE (%), BY REGION, 2022
FIGURE 9 ASIA-PACIFIC: NEURODEGENERATIVE DISEASE MARKET, SHARE (%), BY REGION, 2022
FIGURE 10 REST OF THE WORLD: NEURODEGENERATIVE DISEASE MARKET, SHARE (%), BY REGION, 2022
FIGURE 11 GLOBAL NEURODEGENERATIVE DISEASE MARKET: COMPANY SHARE ANALYSIS, 2022 (%)
FIGURE 12 NOVARTIS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 13 NOVARTIS: SWOT ANALYSIS
FIGURE 14 PFIZER: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 15 PFIZER: SWOT ANALYSIS
FIGURE 16 MERCK SERONO: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 17 MERCK SERONO: SWOT ANALYSIS
FIGURE 18 BIOGEN IDEC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 19 BIOGEN IDEC: SWOT ANALYSIS
FIGURE 20 TEVA PHARMACEUTICALS INDUSTRIES.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 21 TEVA PHARMACEUTICALS INDUSTRIES.: SWOT ANALYSIS
FIGURE 22 UCB: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 23 UCB: SWOT ANALYSIS
FIGURE 24 BOEHRINGER INGELHEIM: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 BOEHRINGER INGELHEIM: SWOT ANALYSIS
FIGURE 26 SANOFI S.A.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 SANOFI S.A.: SWOT ANALYSIS
FIGURE 28 GLAXOSMITHKLINE: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 GLAXOSMITHKLINE: SWOT ANALYSIS